Boston Scientific Wins Guidant Takeover Battle, Ending Fierce Bidding War
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific faces the monumental task of integrating ICD-manufacturer Guidant following a $27.2 bil. acquisition victory over Johnson & Johnson on Jan. 25
You may also be interested in...
“Amicable Agreement”
Regardless of any positives or negatives associated with the protracted CEO transition at Boston Scientific, one primary driver for the arrangement appears to be an agreement hashed out between the company and Johnson & Johnson allowing Mahoney to make the move in the near term without flouting non-compete requirements for former J&J executives.
“Amicable Agreement”
Regardless of any positives or negatives associated with the protracted CEO transition at Boston Scientific, one primary driver for the arrangement appears to be an agreement hashed out between the company and Johnson & Johnson allowing Mahoney to make the move in the near term without flouting non-compete requirements for former J&J executives.
Boston Scientific Acquisition Vote Follows Week Of Bad News For Guidant
Boston Scientific and Guidant shareholders approved the merger of their companies in separate votes March 31, leaving U.S. and European antitrust clearances as the only remaining hurdles to closing the deal